Bridging Gaps, Optimizing Treatment in Patients With LC-FAODs

Annenberg Center for Health Sciences
  • 0,0 (0)
  • Medizin

Patients with long-chain fatty oxidation disorders (LC-FAODs) have historically been treated with diet modification and even-carbon medium-chain triglyceride (MCT) supplementation. In this 45-minute, case-based, modular activity, Sandra van Calcar, PhD, RD, LD, and Jerry Vockley, MD, PhD, address key topics, including disease presentation, historical treatment, emerging treatment with triheptanoin, and nutritional planning specific to patients with LC-FAODs.

Folgen

  1. 14.11.2024

    Clinical Case Vignettes

    Initiating triheptanoin Dosing modification to improve tolerability

  2. 14.11.2024

    Optimizing Triheptanoin Therapy

    Clinical safety and efficacy Initiation and titration Administration considerations Individualizing treatment

  3. 14.11.2024

    Historical Treatment; Introduction of Triheptanoin

    Dietary modification MCT supplementation Triheptanoin mechanism of action

  4. 14.11.2024

    Understanding LC-FAODs

    Autosomal recessive inheritance Carnitine shuttle Newborn screening Clinical features

  • 4 Folgen

Info

Patients with long-chain fatty oxidation disorders (LC-FAODs) have historically been treated with diet modification and even-carbon medium-chain triglyceride (MCT) supplementation. In this 45-minute, case-based, modular activity, Sandra van Calcar, PhD, RD, LD, and Jerry Vockley, MD, PhD, address key topics, including disease presentation, historical treatment, emerging treatment with triheptanoin, and nutritional planning specific to patients with LC-FAODs.

Informationen